Novo Nordisk's Wegovy Gets U.S. Approval for Liver Disease, Sam Altman Warns of AI Bubble
The Rundown
00:00
Novo Nordisk's Wegovy Approval and Market Dynamics in Pharma and Stocks
This chapter examines Novo Nordisk's Wegovy approval for treating liver disease, along with stock market reactions and competition from Eli Lilly. It also highlights the rising applications of GLP-1 drugs and Soho House's shift to private ownership amid falling stock prices.
Transcript
Play full episode
